Docosahexaenoic acid loaded lipid nanoparticles with bactericidal activity against Helicobacter pylori

International Journal of Pharmaceutics

Volumn 519, Issue 1-2, 2017, Pages 128-137

  Seabra, Catarina Leal ^a,b,c   Nunes, Cláudia ^c   Gomez Lazaro, Maria ^a,b   Correia, Marta ^d   Machado, José Carlos ^a,c,e   Gonçalves, Inês C ^a,b   Reis, Celso A ^a,c,e   Reis, Salette ^c   Martins, M Cristina L ^a,b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF ALGARVE   (Portugal)

^e University of Porto   (Portugal)

Author keywords

Docosahexaenoic acid (DHA); Helicobacter pylori; Nanostructured lipid carriers (NLC); Polyunsaturated fatty acid (PUFA)

Indexed keywords

DOCOSAHEXAENOIC ACID; LIPID; MIGLYOL; NANOPARTICLE; SURFACTANT; ANTIINFECTIVE AGENT; DRUG CARRIER; FISH OIL; NANOMATERIAL; POLYSORBATE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BIOCOMPATIBILITY; COLONY FORMING UNIT; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; MTT ASSAY; NANOENCAPSULATION; PERIPLASM; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROPHOTOMETRY; CHEMISTRY; DRUG EFFECTS; HELICOBACTER INFECTIONS; MICROBIOLOGY; PARTICLE SIZE; STOMACH; TUMOR CELL LINE;

ANTI-BACTERIAL AGENTS; CELL LINE, TUMOR; DOCOSAHEXAENOIC ACIDS; DRUG CARRIERS; FISH OILS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LIPIDS; NANOPARTICLES; NANOSTRUCTURES; PARTICLE SIZE; POLYSORBATES; STOMACH; SURFACE-ACTIVE AGENTS;

EID: 85010199517     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2017.01.014     Document Type: Article

References (43)

1. AmericanCancerSociety, Global Cancer Facts & Figs. 3rd ed., 2015, American Cancer Society, Atlanta.
2. Amieva, M., Peek, R.M. Jr., Pathobiology of Helicobacter pylori-induced gastric cancer. Gastroenterology 150 (2016), 64–78.
3. Beloqui, A., Solinis, M.A., Rodriguez-Gascon, A., Almeida, A.J., Preat, V., Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine 12 (2016), 143–161.
4. Blackburn, P., 1997. Polysorbate-containing compositions and their use against Helicobacter. European Patent Office WO/1997/036600.
5. Brown, J.C., Huang, G., Haley-Zitlin, V., Jiang, X., Antibacterial effects of grape extracts on Helicobacter pylori. Appl. Environ. Microbiol. 75 (2009), 848–852.
6. Cerreto, F., Paolicelli, P., Cesa, S., Abu Amara, H.M., D'Auria, F.D., Simonetti, G., Casadei, M.A., Solid lipid nanoparticles as effective reservoir systems for long-term preservation of multidose formulations. AAPS PharmSciTech 14 (2013), 847–853.
7. Chaput, C., Labigne, A., Boneca, I.G., Characterization of Helicobacter pylori lytic transglycosylases Slt and MltD. J. Bacteriol. 189 (2007), 422–429.
8. Correa, P., Houghton, J., Carcinogenesis of Helicobacter pylori. Gastroenterology 133 (2007), 659–672.
9. Correia, M., Michel, V., Matos, A.A., Carvalho, P., Oliveira, M.J., Ferreira, R.M., Dillies, M.A., Huerre, M., Seruca, R., Figueiredo, C., Machado, J.C., Touati, E., Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization. PLoS One, 7, 2012, e35072.
10. Correia, M., Michel, V., Osório, H., El Ghachi, M., Bonis, M., Boneca, I.G., De Reuse, H., Matos, A.A., Lenormand, P., Seruca, R., Figueiredo, C., Machado, J.C., Touati, E., Crosstalk between Helicobacter pylori and Gastric Epithelial Cells Is Impaired by Docosahexaenoic Acid. PloS One, 8, 2013, e60657.
11. Dai, J., Shen, J., Pan, W., Shen, S., Das, U.N., Effects of polyunsaturated fatty acids on the growth of gastric cancer cells in vitro. Lipids Health Dis., 12, 2013, 71.
12. Das, S., Chaudhury, A., Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 12 (2011), 62–76.
13. Desbois, A.P., Lawlor, K.C., Antibacterial activity of long-chain polyunsaturated fatty acids against Propionibacterium acnes and Staphylococcus aureus. Mar. Drugs 11 (2013), 4544–4557.
14. Desbois, A.P., Smith, V.J., Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential. Appl. Microbiol. Biotechnol. 85 (2010), 1629–1642.
15. Desbois, A.P., Potential applications of antimicrobial fatty acids in medicine, agriculture and other industries. Recent Pat. Antiinfect. Drug Discov. 7 (2012), 111–122.
16. Goncalves, I.C., Henriques, P.C., Seabra, C.L., Martins, M.C., The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection. Expert Rev. Anti Infect. Ther. 12 (2014), 981–992.
17. ISO10993-5, Part 5: tests for in vitro cytotoxicity. Biological Evaluation of Medical Devices, 3rd ed., 2009, International Organization for Standardization, Geneva, Switzerland.
18. Iemsam-Arng, J., Ketchart, O., Rattana-Amron, T., Wutikhun, T., Tapaneeyakorn, S., Modified NLC-loaded coumarin for pharmaceutical applications: the improvement of physical stability and controlled release profile. Pharm. Dev. Technol., 2015, 1–8.
19. Jung, S.W., Thamphiwatana, S., Zhang, L., Obonyo, M., Mechanism of antibacterial activity of liposomal linolenic acid against Helicobacter pylori. PLoS One, 10, 2015, e0116519.
20. Lee, S.E., Lim, J.W., Kim, H., Activator protein-1 mediates docosahexaenoic acid-induced apoptosis of human gastric cancer cells. Ann. N. Y. Acad. Sci. 1171 (2009), 163–169.
21. Lopes, D., Nunes, C., Martins, M.C., Sarmento, B., Reis, S., Eradication of Helicobacter pylori: past, present and future. J. Control Release 189 (2014), 169–186.
22. Müller, R.H., Mäder, K., Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (2000), 161–177.
23. Malfertheiner, P., Megraud, F., O'Morain, C.A., Atherton, J., Axon, A.T.R., Bazzoli, F., Gensini, G.F., Gisbert, J.P., Graham, D.Y., Rokkas, T., El-Omar, E.M., Kuipers, E.J., Management of Helicobacter pylori infection- the Maastricht IV/Florence Consensus Report. Gut, 61, 2012, 646e664.
24. Matysiak-Budnik, T., Megraud, F., Helicobacter pylori infection and gastric cancer. Eur. J. Cancer 42 (2006), 708–716.
25. Mehnert, W., Mäder, K., Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47 (2001), 165–196.
26. Meier, R., Wettstein, A., Drewe, J., Geiser, H.R., Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 15 (2001), 851–855.
27. Muller, R.H., Shegokar, R., Keck, C.M., 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol. 8 (2011), 207–227.
28. Neves, A.R., Lucio, M., Martins, S., Lima, J.L., Reis, S., Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int. J. Nanomed. 8 (2013), 177–187.
29. Obeidat, W.M., Schwabe, K., Müller, R.H., Keck, C.M., Preservation of nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 76 (2010), 56–67.
30. Parreira, P., Fátima Duarte, M., Reis, C.A., Martins, M.C.L., Helicobacter pylori infection: a brief overview on alternative natural treatments to conventional therapy. Crit. Rev. Microbiol., 2016, 1–12.
31. Paulo, L., Oleastro, M., Gallardo, E., Queiroz, J.A., Domingues, F., Anti-Helicobacter pylori and urease inhibitory activities of resveratrol and red wine. Food Res. Int. 44 (2011), 964–969.
32. Petschow, B.W., Batema, R.P., Ford, L.L., Susceptibility of Helicobacter pylori to bactericidal properties of medium-chain monoglycerides and free fatty acids. Antimicrob. Agents Chemother. 40 (1996), 302–306.
33. Pinho, S.S., Carvalho, S., Marcos-Pinto, R., Magalhaes, A., Oliveira, C., Gu, J., Dinis-Ribeiro, M., Carneiro, F., Seruca, R., Reis, C.A., Gastric cancer: adding glycosylation to the equation. Trends Mol. Med. 19 (2013), 664–676.
34. Poonia, N., Kharb, R., Lather, V., Pandita, D., Nanostructured lipid carriers: versatile oral delivery vehicle. Future Sci. OA, 2, 2016, FSO135.
35. Romero, C., Medina, E., Vargas, J., Brenes, M., De Castro, A., In vitro activity of olive oil polyphenols against Helicobacter pylori. J. Agric. Food Chem. 55 (2007), 680–686.
36. Santucci, A., Figura, N., Spreafico, A., Cavallo, G., Marcolongo, R.F., 2013. Compositions for treating Helicobacter pylori infection. European Patent Office WO2011IT00175.
37. Sun, C.Q., O'Connor, C.J., Roberton, A.M., Antibacterial actions of fatty acids and monoglycerides against Helicobacter pylori. FEMS Immunol. Med. Microbiol. 36 (2003), 9–17.
38. Tamjidi, F., Shahedi, M., Varshosaz, J., Nasirpour, A., Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules. Innov. Food Sci. Emerg. Technol. 19 (2013), 29–43.
39. Taneja, A., Singh, H., Challenges for the delivery of long-chain n-3 fatty acids in functional foods. Annu. Rev. Food Sci. Technol. 3 (2012), 105–123.
40. Thompson, L., Cockayne, A., Spiller, R.C., Inhibitory effect of polyunsaturated fatty acids on the growth of Helicobacter pylori: a possible explanation of the effect of diet on peptic ulceration. Gut 35 (1994), 1557–1561.
41. Vakil, N., Helicobacter pylori treatment: a practical approach. Am. J. Gastroenterol. 101 (2006), 497–499.
42. Zhuang, C.-Y., Li, N., Wang, M., Zhang, X.-N., Pan, W.-S., Peng, J.-J., Pan, Y.-S., Tang, X., Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int. J. Pharm. 394 (2010), 179–185.
43. del Pozo-Rodriguez, A., Solinis, M.A., Gascon, A.R., Pedraz, J.L., Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur. J. Pharm. Biopharm. 71 (2009), 181–189.